Anthony F Shields MD PhD

Oncology•Detroit, MI

Gastrointestinal Cancer

Associate Center Director, Karmanos Cancer Institute, Professor of Oncology, Wayne State University

Join to View Full Profile

4100 John R Street, HW04HOKarmanos Cancer InstituteDetroit, MI 48201
Phone+1 800-527-6266
Fax+1 313-576-8767

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1984
University of WashingtonResidency, Internal Medicine, 1979 - 1981
Massachusetts Institute of TechnologyPhD, Biology, 1973 - 1979
Harvard Medical SchoolClass of 1979

Certifications & Licensure

MI State Medical License 1995 - 2027
WA State Medical License 1980 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy Start of enrollment: 2007 Mar 30
Terminated
Not Applicable
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Start of enrollment: 2011 Aug 17
Completed
Phase 1
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy Start of enrollment: 2012 Jun 01
Completed
Not Applicable
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
Completed
Not Applicable
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2016 May 16
COMPLETED
PHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Start of enrollment: 2020 Jan 07
TERMINATED
PHASE1, PHASE2
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Start of enrollment: 2018 Jun 20
COMPLETED
PHASE2
Roles: Contact, Principal Investigator
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Start of enrollment: 2018 Oct 24
Terminated
Phase 1
Roles: Contact
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
COMPLETED
NA
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance).
En Cheng, Qian Shi, Anthony F Shields, Xiaonan Xue, Thomas E Rohan
Journal of the National Cancer Institute. 2025-09-25
3 citations
Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer Patients.
Daniel Magee, Valeriy Domenyuk, Jim Abraham, Nieves Perdigones Borderias, Jeff Swensen
Clinical Cancer Research. 2025-07-01
1 citations
Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes.
Pooja Mittal, Francesca Battaglin, Yasmine Baca, Joanne Xiu, Alex Farrell
International Journal of Cancer. 2025-04-15

Press Mentions

Free Cancer Survivors Fitness Program Offered by Karmanos and WSUJune 19th, 2025
Free Fitness Classes for Cancer Survivors Return to Commerce Township, Presented by Karmanos and Wayne State UniversityJune 19th, 2025
Phase 2 Trial Now Recruiting for Nab-Paclitaxel, Gemcitabine, and TheraBionic P1 in Metastatic Pancreatic CancerMay 15th, 2025
Join now to see all

Grant Support

NCI National Clinical Trials Network – Network Lead Academic Participating SiteWAYNE STATE UNIVERSITY2019–2025
Imaging Cellular Stress And Treatment Response Using Positron Emission TomographyNational Cancer Institute2010–2012
Develpmental TherapeuticsNational Cancer Institute2005–2009
Labeled Thymidine -- Development As A PET Imaging AgentNational Cancer Institute2004–2008
Labeled Thymidine-Development As A PET Imaging AgentNational Cancer Institute2005–2006
Midcareer Investigator AwardNational Cancer Institute1999–2003
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1997–2003
Developmental TherapeuticsNational Cancer Institute2001–2002
PET Imaging Of Drug Kinetics And PathwaysNational Cancer Institute1999–2002
Metabolic Measurement In Lymphoma Treated With ChemotherapyNational Cancer Institute1996–1997
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1988–1994
Labeled Thymidine: Development As A PET Imaging AgentNational Cancer Institute1987–1993
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1985–1987